Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
2 hedge funds and large institutions have $4.9M invested in Seelos Therapeutics, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
217% more call options, than puts
Call options by funds: $149K | Put options by funds: $47K
0% more funds holding
Funds holding: 2 → 2 (0)
30% less capital invested
Capital invested by funds: $7.03M → $4.9M (-$2.13M)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$35K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$486 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $5K | – | – | – |
|
27
Citigroup
New York
| $4K | – | – | – |
|
|
HDIM
28
Hanson & Doremus Investment Management
Burlington,
Vermont
| $2K | – | – | – |
|
|
U
29
UBS
Zurich,
Switzerland
| $2K | – | – | – |
|
|
HI
30
Hudock Inc
Williamsport,
Pennsylvania
| $1K | – | – | – |
|
|
SM
31
Sabby Management
Miami Beach,
Florida
| $26 | – | – | – |
|
32
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $6 | – | – | – |
|
|
33
BNP Paribas Financial Markets
Paris,
France
| – | -$486 | – | – |
|
|
GC
34
Guggenheim Capital
Chicago,
Illinois
| – | -$35K | – | – |
|
SEEL Hedge Fund Activity: Q3 2014 in Review
2 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q3 2014, worth a combined $4.9M — down 30% from $7.03M a quarter earlier.
Fund positioning in SEEL was balanced in Q3 2014: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Guggenheim Capital, cutting an estimated $35K.
- 2 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q3 2014, unchanged from Q2 2014.
- Funds reported $4.9M of Seelos Therapeutics, Inc. Common Stock stock for Q3 2014, down 30% quarter-over-quarter.
- 0 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q3 2014 and 0 closed out.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q3 2014 was Guggenheim Capital, an estimated $35K sold.
Based on aggregated 13F filings for Q3 2014.